ClinicalTrials.gg
RecruitingNCT07727798IMPROVEUpdated Jul 27, 2026

Intrathecal Pump Refills at Home or at the Hospital

An interventional study of Refill at the hospital and Refill at home in Intrathecal Pump Refill, sponsored by Moens Maarten. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Moens Maarten · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The IMPROVE study is a randomized, controlled, cross-over trial designed to compare intrathecal pump refills performed at home with those carried out in the hospital. Intrathecal drug delivery (IDD) is used in patients with chronic pain or severe spasticity. Use of IDD requires the performance of pump refills about 4-6 times a year which may be a burdensome and stressful experience for patients and their caregivers. Hospital visits can increase stress, pain, and caregiver strain, while early pilot studies suggest home-based refills may be both safe and more comfortable.

Eighty-two adult patients in Belgium with an implanted intrathecal pump will be enrolled in the IMPROVE study. Each participant will undergo four refill procedures: two at home and two at the hospital, in randomized order.

02

Conditions studied

  • Intrathecal Pump Refill

Keywords

  • Intrathecal drug delivery
  • intrathecal pump therapy
  • neuromodulation
  • refill
  • patient comfort
  • telemedicine
  • remote care
  • hospital to home transition
03

In context

Lead sponsor

Moens Maarten is the lead sponsor of 22 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Actively receiving Intrathecal drug delivery
  • Stable medication dosage for at least 3 months
  • Dutch, French or English speaking adults

Exclusion criteria

Exclusion Criteria:

  • \< 6 months
  • Patients planned for but not yet received Intrathecal drug delivery implant
  • No residence in Belgium
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Active comparator
    Refill at home

    Procedure: Refill at home

  • Active comparator
    Refill at the hospital

    Procedure: Refill at the hospital

Interventions

  • ProcedureRefill at the hospital

    Intrathecal pump refill procedure conducted at the hospital

  • ProcedureRefill at home

    Intrathecal pump refill procedure conducted at the home of the patient

06

What researchers measure

Primary outcomes

  1. Patient Comfort

    Patient comfort is evaluated with the General Comfort Questionnaire (GCQ), a self-reported instrument consisting of 48 items that reflect the physical, spiritual, environmental and social dimension. Responses are rated on a four-point Likert scale ranging from "strongly disagree" to "strongly agree". Some items are reverse scored during data processing, with higher overall scores indicating greater levels of comfort.

    Time frame: At baseline and immediately after each intervention.

Secondary outcomes

  1. Quality of life

    The McGill Quality of Life Questionnaire (MQOL) will measure quality of life and consists of 17 questions. Higher scores reflect a better quality of life.

    Time frame: At baseline and immediately after each intervention.

  2. Health-related quality of life

    The EuroQol with five dimensions and five levels (EQ-5D-5L) will be assessed to measure health-related quality of life. Higher scores reflect a better quality of life.

    Time frame: At baseline and immediately after each intervention.

  3. Pain intensity

    The Visual Analogue Scale (VAS - 100 mm) in electronic format will be used for the assessment of current pain intensity.

    Time frame: At baseline and immediately after each intervention.

  4. Pain interference

    The NIH-funded Patient-Reported Outcomes Measurement Information System Pain Interference measure assesses the impact of pain on key aspects of an individual's life. It evaluates the extent to which pain disrupts engagement in social, cognitive, emotional, physical, and recreational activities.

    Time frame: At baseline and immediately after each intervention.

  5. Stress

    Saliva samples will be collected to measure cortisol levels with synthetic salivettes.

    Time frame: 5 minutes before the refill, immediately after the refill and 10 minutes after the refill procedure.

  6. Anxiety

    Patient anxiety will be assessed through the State Trait Anxiety Inventory (STAI). This questionnaire consists of 40 Likert-type items on a four-point scale. Higher scores are indicating higher levels of anxiety.

    Time frame: At baseline and immediately after each intervention.

  7. Self-efficacy

    The General Self-Efficacy (GSE) Scale is a 10-item self-report questionnaire used to assess perceived self-efficacy.

    Time frame: At baseline and immediately after each intervention.

  8. Caregiver burden

    To evaluate caregiver burden, the Zarit Burden Interview (ZBI) questionnaire will be completed. This 12-item self-report instrument assesses caregiver burden and is a shortened version of the original 22-item Zarit Burden Scale. The total score ranges from 0 to 48, with higher totals reflecting more significant caregiver burden.

    Time frame: At baseline and immediately after each intervention.

  9. Patient satisfaction

    Patient satisfaction is evaluated with a seven-point Likert scale asking the patient to rate the overall level of satisfaction with the refill at home.

    Time frame: Immediately after each refill procedure at home (intervention).

  10. Tele-monitoring quality

    The quality of tele-monitoring will only be evaluated after a home-filling. This will be examined using three different Likert scales to score 1) quality of audio, 2) quality of video, and 3) overall quality of the teleconsultation.

    Time frame: Immediately after each refill procedure at home (intervention).

  11. Duration of refill

    The time required for the full procedure will be recorded.

    Time frame: Immediately after each intervention.

  12. Safety of the refill procedure at home

    Patients will evaluate the overall safety of the procedure using a seven-point Likert scale. In addition, the researcher will assess safety on three levels: (1) overall perceived safety of the procedure using a seven-point Likert scale; (2) environmental safety, assessed through an open-ended question addressing any situations perceived as unsafe; and (3) the ability to perform the procedure in a clean and sterile manner, also evaluated via an open-ended question.

    Time frame: Immediately after each refill procedure at home (intervention).

  13. Health expenditure

    Expenditures related to in hospital care will be extracted from hospital claims data. All other healthcare-related costs will be gathered through telephone interviews with patients, conducted four weeks after the first and second medication refills. During these calls, researchers will ask patients whether they have had any medical consultations, hospital admissions, adverse events, changes in medication, or incurred any additional healthcare costs.

    Time frame: Four weeks after the first and second intervention.

  14. Patient preference

    After the fourth refill procedure, patients will be asked to indicate their preference (refill at home, refill in the hospital, no preference or other) for the location of their refills in the future.

    Time frame: Immediately after the final study intervention

  15. Discrete choice experiment

    After the fourth refill procedure, patients will be presented with a discrete choice experiment to evaluate their preferences across several scenarios.

    Time frame: Immediately after the final study intervention

07

Study locations

1 of 1 sites recruiting
  • UZ Brussel
    Jette, 1090, Belgium
    Recruiting
    • Maarten Moens, MD PhD · Contact
    • Ulrike Van Hoey, MSc · Sub investigator
    • Britt Winnepenninckx, MSc · Sub investigator
    • Koen Putman, MSc, PhD · Sub investigator
    • Lisa Goudman, MSc, PhD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Oct 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Jul 27, 2026
StartActual
Oct 15, 2025
Primary completionEst.
Oct 1, 2028
CompletionEst.
Oct 1, 2028
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07727798
Lead sponsor
Moens Maarten
Responsible party
Moens Maarten (principal investigator, Universitair Ziekenhuis Brussel) — Sponsor-investigator
First posted
Jul 27, 2026
Start date
Oct 15, 2025
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Jul 27, 2026

Study contacts

Maarten Moens, MD PhD
Contact
stimulusresearchgroup@gmail.com
+3224775514
Lisa Goudman, PhD
Contact
lisa.goudman@vub.be
+32472412507

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion